Advisory Committee Rejects Avandia Vs. Actos Comparison Data

FDA's advisory panel for the review of cardiovascular safety concerns with GlaxoSmithKline's Avandia refused to consider unvetted data on Takeda's competing thiazolidinedione Actos because the information has not yet been fully analyzed by FDA